Avatrombopag for adults with immune low platelets
Treatments studied
Part of Blood & lymphatic, Immune system & allergy, Skin clinical trials.
This trial studies avatrombopag to raise platelet counts in adults with immune thrombocytopenia (ITP) caused by autoimmune conditions. It may help reduce bleeding risk when platelet levels are very low.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older, and you can sign informed consent
- Your ITP is related to an autoimmune condition (like lupus, Sjogren’s, or rheumatoid arthritis) or confirmed by specific blood test clues
- Your platelet count is below 30 (in the trial’s units) at screening
- You either could not benefit from similar ITP medicines (eltrombopag or romiplostim-related drugs) or cannot take them due to side effects or reasons from your doctor
- Your current ITP treatment is finished, stable, or being reduced in the 2 weeks before enrollment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new platelet-raising medicine, avatrombopag, in children with ITP who have already tried eltrombopag. It aims to see if switching to avatrombopag can safely increase platelet counts and reduce bleeding.
This study tests whether adding another medicine (telitacicept) to a standard platelet-boosting drug (eltrombopag) works better than eltrombopag alone for adults with ITP that hasn't improved with steroids. The goal is to help raise your platelet counts and reduce bleeding risk.
This study tests whether a drug called hetrombopag can help your immune system stop attacking your platelets, so your platelet count stays up even after stopping the drug. It's for people with ITP who responded well to hetrombopag but want to see if they can stay in remission without it.
This trial tests a medicine called ATRA (a form of vitamin A) to see if it can help adults with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing bleeding and bruising. It is for people who have already tried standard treatments without lasting success.
This study looks at how doctors treat immune thrombocytopenia (ITP)—a blood condition where your body attacks its own platelets—using a drug called eltrombopag. Researchers want to understand treatment patterns and outcomes in real-world practice to improve care.
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
Hear when a new Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.